Entities / Company
Tempus.
biotechnology company based in Chicago, Illinois
- Reports this week
- 2
- Active events
- 4
- Connections
- 109
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Tempus is scheduled to participate in a conference in New York City on September 4, 2025.Some support2 reports1 development inside
-
Tempus AI, led by Eric Lefkofsky, is acquiring Paige to enhance its digital pathology datasets.Some support2 reports1 development inside
-
Leica Biosystems integrates products from Paige and Tempus AI into its platform, adding Paige products to its AI Store.Some support1 report
-
MarketBeat highlighted SentinelOne and Tempus AI as AI stocks on September 14, 2026.Some support2 reports
Earlier this month
-
Tempus listed on Nasdaq, filed disclosures with the SEC, and received research reports from Jefferies Financial Group.Well supported7 reports
-
Tempus AI has named AstraZeneca as a customer, and Morgan Stanley boosted its revenue outlook.Some support2 reports
-
Tempus and Biovica International mutually ended a potential partnership agreement while reviewing US commercial strategy.Some support2 reports
-
Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.Some support2 reports
One to three months ago
-
Hut 8 Corp. operates data centers for digital assets mining, and MarketBeat lists stocks as AI stocks to watch.Some support2 reports
-
Tempus and Bios Life have formed a new multi-year data alliance.Some support1 report
-
Tempus AI is part of the Tempus group, and Sophia Genetics partners with AstraZeneca while Tempus collaborates with Boehringer Ingelheim on cancer therapies.Some support3 reports2 developments inside
-
Tempus AI is headquartered in Chicago, Illinois, and operates within the US healthcare market.Some support1 report
-
Tempus listed on the NASDAQ stock exchange, providing diagnostic data and AI tools to facilitate drug approval processes.Well supported6 reports1 development inside
-
ARK purchased shares of Tempus AI and filed regulatory documents with the SEC, pivoting toward AI health plays.Well supported3 reports
-
Tempus and ServiceNow are pursuing opportunities related to AI spending.Some support1 report
-
Tempus AI buys Personalis in a strategic move.Some support2 reports
-
Tempus operates in the global healthcare technology sector in Africa.Some support2 reports
-
Tempus and Natera are operating in the competitive field of ctDNA diagnostics.Some support1 report1 development inside
-
Tempus and Natera are subject to new financial analysis from BNP Paribas and William Blair regarding valuation and strategic fit.Some support1 report
-
Collaboration between Personalis and Tempus established, with Tempus serving as Personalis’ exclusive commercial partner and expanding to include colorectal cancer.Some support1 report1 development inside
-
Eric Lefkofsky is CEO of Tempus, and the company utilizes Personalis technology which has successfully secured Medicare coverage.Some support2 reports
-
BlackRock holds a significant stake in Tempus, an AI healthcare technology company.Some support2 reports
Gone quiet
No new reports in 90+ days-
Tempus AI advances precision medicine in the US, and MarketBeat's stock screener tool is used in the US.Some support5 reports
-
The company Tempus is seeking FDA clearance for its technology and listed on the NASDAQ stock exchange.Some support2 reports
-
MarketBeat highlighted Tempus AI as a stock to watch on June 24th.Some support1 report
-
Talkspace and Tempus are being compared on market viability and growth, with Talkspace operating as a virtual behavioral healthcare company.Some support1 report
-
MarketBeat featured companies in the AI sector on June 21, 2026.Some support1 report
-
Tempus and Memorial Sloan Kettering Cancer Center launched an open-source digital pathology consortium.Some support1 report
-
Novartis, Takeda, and United Therapeutics signed data licensing deals with Tempus AI.Speculative2 reports
-
Guggenheim raised its price target for Tempus AI on July 4, 2025, citing the company's progress.Speculative1 report
-
Tradr launched leveraged ETFs tracking CoreWeave, Constellation Energy, SMR, and Tempus AI, tied to the AI data center build-out theme.Some support1 report1 development inside
-
Tempus AI is working to help providers stay current, and Our Lady of Mercy College integrated Tempus Next into its EMR system.Some support2 reports
-
Cramer noted on July 15, 2025, that Tempus AI is currently losing money.Some support1 report
-
Tempus AI and Amazon Web Services are key players in the health tech AI ecosystem.Some support1 report
-
Patient Capital Management highlighted Tempus AI in its strategy on July 18, 2025.Some support1 report
-
Tempus AI is noted for strong enthusiasm regarding artificial intelligence.Some support1 report
-
Ambry Genetics is now a wholly owned subsidiary of Tempus AI.Speculative1 report
-
Tempus AI outperformed the life sciences industry's negative return and exceeded the broader market's return on August 18, 2025.Some support2 reports
-
Tempus AI and NeoGenomics completed an acquisition to strengthen AI leadership in healthcare.Some support1 report1 development inside
-
Tempus AI is accelerating foundation model development by utilizing digital slide archives from Memorial Sloan Kettering Cancer Center and Microsoft Azure.Some support1 report
-
Johnson & Johnson, Boston Scientific, and Tempus AI are major medical device manufacturers and key players in AI-enabled medical devices.Some support1 report2 developments inside
-
MarketBeat featured Tempus AI and BigBear.ai as stocks to watch on May 27, 2026.Some support9 reports
-
Tempus AI and Northwestern Medicine partnered to enhance AI-powered clinical care and boost investor confidence.Some support2 reports
-
Tempus AI and AstraZeneca announced a foundational model partnership.Some support4 reports
-
FDA granted 510(k) clearance for Tempus AI's ECG-Low EF software.Well supported4 reports
-
Tempus AI's selling activity was reversed following the dismissal of a critical report by TD Cowen.Speculative1 report
-
Paige, acquired by Tempus AI, has received FDA clearance, while AI stocks continue to benefit from onshoring and tariff trends.Some support2 reports1 development inside
-
Analyst firm TD Cowen noted that due to genomic volume growth, Tempus AI benefits from Trump-era tariffs and onshoring trends.Some support1 report
-
Pelosi's trades fueled speculative sentiment around Tempus AI as of June 25, 2025.Speculative1 report
-
Recursion Pharmaceuticals, Merck KGaA, and Tempus expanded collaborations to leverage multimodal datasets and launch AI models for drug discovery.Some support1 report
-
Eric Lefkofsky joined Tempus as Founder and CEO, and Jim Rogers joined as CFO, both on July 22, 2025.Some support1 report
-
Eric Lefkofsky was named the Founder and CEO of Tempus on August 8, 2025.Some support2 reports
-
Tempus stock underperformed the S&P 500 composite on August 8, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Tempus this week
News at the entities that move Tempus most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Tempus
-
Merck StructuralEli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Moves Tempus
-
AstraZeneca OperationalAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Tempus
-
Morgan Stanley TransactionalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Tempus
-
TD Cowen Mentioned togetherAnalyst downgraded Ag Growth International Inc. due to debt management risks.Moves Tempus
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Tempus
Connections
The 32 strongest of 109, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Merck Structural
Tempus supplies diagnostic data and AI tools and partners with Merck on clinical trials.
-
Personalis (United States) Structural
Personalis and Tempus maintain an exclusive commercial and strategic partnership focused on cancer indications.
-
AstraZeneca Operational
Tempus and AstraZeneca are engaged in a partnership to jointly develop an oncology foundation model, supported by a $200M data licensing deal.
-
Eric Lefkofsky Structural
Eric Lefkofsky serves as the Founder and CEO of Tempus.
-
Nasdaq Structural
Tempus is formally listed and trades on the Nasdaq stock exchange.
-
FDA Structural
FDA formally regulates and grants necessary clearances for Tempus's medical software and technologies.
-
Nadja West Structural
Nadja West holds the formal position of Director at Tempus AI.
-
Morgan Stanley Transactional
Morgan Stanley's financial analysis positively influenced Tempus's revenue outlook and potential revenue streams.
Show all 32 connections
-
TD Cowen Mentioned together
TD Cowen provides investment ratings and commentary on Tempus AI.
-
Medicare Structural
Tempus's business model relies on Medicare coverage, reimbursement structures, and indications for its technology to operate and generate revenue.
-
SEC Structural
Tempus is required to file disclosures with the SEC as part of regulatory compliance.
-
Memorial Sloan Kettering Cancer Center Operational
The two entities are currently collaborating in an open-source digital pathology consortium.
-
Leica Biosystems Operational
Leica Biosystems has functionally integrated Tempus's AI products into its core platform.
-
Ark Invest Structural
Ark Invest holds a 4% weightage of Tempus AI stock as one of its top holdings.
-
Nancy Pelosi Transactional
Nancy Pelosi has held shares in Tempus, with her investment activity influencing market sentiment.
-
Moderna Operational
Moderna and Tempus are collaborating partners on the INTerpath-001 clinical trial, which yielded successful Phase 3 results.
-
Natera Operational
Tempus and Natera are direct competitors vying for market share in the ctDNA diagnostics space.
-
Donald Trump Operational
A's political platform, specifically regarding tariffs and onshoring, creates a favorable market environment for B's business model.
-
GSK Structural
GSK provides essential diagnostic data and AI tools that are utilized by Tempus in its operations.
-
BlackRock Structural
BlackRock holds a significant financial stake in Tempus, establishing a structural investment relationship.
-
Raymond James Financial Operational
Raymond James Financial operates by setting price objectives on Tempus AI shares, indicating active market coverage.
-
William P. Blair Mentioned together
William P. Blair provides market coverage and favorable views on Tempus.
-
Talkspace Operational
The companies are compared in the market regarding their viability and growth potential.
-
Jefferies Financial Group Operational
Jefferies Financial Group provides professional research reports and ratings on Tempus.
-
Africa Shared context
The company operates within the global healthcare technology sector, which includes Africa.
-
Freedom Capital Mentioned together
Freedom Capital began market coverage and tracking of Tempus AI.
-
AI, Inc. Mentioned together
Tempus is described as a technology company that utilizes AI to advance precision medicine.
-
BigBear.ai Operational
The two companies are actively competing for market share and contracts within the artificial intelligence sector.
-
MarketBeat Mentioned together
MarketBeat consistently reports on Tempus, featuring it as a stock to watch within the AI sector.
-
Illinois Shared context
Tempus AI is geographically situated within the borders of the state of Illinois.
-
Chicago Shared context
Tempus is a biotechnology company that is based and operates out of Chicago.
-
ServiceNow Operational
Both companies are actively pursuing opportunities within the AI spending market.
History
Events by the month they beganSeptember 2026
3 eventsAugust 2026
3 eventsJuly 2026
8 events- Tempus listed on Nasdaq, filed disclosures with the SEC, and received research reports from Jefferies Financial Group.
- Tempus AI is headquartered in Chicago, Illinois, and operates within the US healthcare market.
- Tempus and ServiceNow are pursuing opportunities related to AI spending.
- Tempus AI buys Personalis in a strategic move.
- Tempus operates in the global healthcare technology sector in Africa.
- Tempus and Natera are subject to new financial analysis from BNP Paribas and William Blair regarding valuation and strategic fit.
- Eric Lefkofsky is CEO of Tempus, and the company utilizes Personalis technology which has successfully secured Medicare coverage.
- BlackRock holds a significant stake in Tempus, an AI healthcare technology company.
Show 1 earlier month
June 2026
39 events- Tempus is scheduled to participate in a conference in New York City on September 4, 2025.
- Tempus AI, led by Eric Lefkofsky, is acquiring Paige to enhance its digital pathology datasets.
- Tempus and Biovica International mutually ended a potential partnership agreement while reviewing US commercial strategy.
- Tempus AI is part of the Tempus group, and Sophia Genetics partners with AstraZeneca while Tempus collaborates with Boehringer Ingelheim on cancer therapies.
- Tempus listed on the NASDAQ stock exchange, providing diagnostic data and AI tools to facilitate drug approval processes.
- ARK purchased shares of Tempus AI and filed regulatory documents with the SEC, pivoting toward AI health plays.
- Tempus and Natera are operating in the competitive field of ctDNA diagnostics.
- Collaboration between Personalis and Tempus established, with Tempus serving as Personalis’ exclusive commercial partner and expanding to include colorectal cancer.
- Tempus AI advances precision medicine in the US, and MarketBeat's stock screener tool is used in the US.
- The company Tempus is seeking FDA clearance for its technology and listed on the NASDAQ stock exchange.
- MarketBeat highlighted Tempus AI as a stock to watch on June 24th.
- Talkspace and Tempus are being compared on market viability and growth, with Talkspace operating as a virtual behavioral healthcare company.
- MarketBeat featured companies in the AI sector on June 21, 2026.
- Tempus and Memorial Sloan Kettering Cancer Center launched an open-source digital pathology consortium.
- Novartis, Takeda, and United Therapeutics signed data licensing deals with Tempus AI.
- Guggenheim raised its price target for Tempus AI on July 4, 2025, citing the company's progress.
- Tradr launched leveraged ETFs tracking CoreWeave, Constellation Energy, SMR, and Tempus AI, tied to the AI data center build-out theme.
- Tempus AI is working to help providers stay current, and Our Lady of Mercy College integrated Tempus Next into its EMR system.
- Cramer noted on July 15, 2025, that Tempus AI is currently losing money.
- Tempus AI and Amazon Web Services are key players in the health tech AI ecosystem.
- Patient Capital Management highlighted Tempus AI in its strategy on July 18, 2025.
- Tempus AI is noted for strong enthusiasm regarding artificial intelligence.
- Ambry Genetics is now a wholly owned subsidiary of Tempus AI.
- Tempus AI outperformed the life sciences industry's negative return and exceeded the broader market's return on August 18, 2025.
- Tempus AI and NeoGenomics completed an acquisition to strengthen AI leadership in healthcare.
- Tempus AI is accelerating foundation model development by utilizing digital slide archives from Memorial Sloan Kettering Cancer Center and Microsoft Azure.
- Johnson & Johnson, Boston Scientific, and Tempus AI are major medical device manufacturers and key players in AI-enabled medical devices.
- MarketBeat featured Tempus AI and BigBear.ai as stocks to watch on May 27, 2026.
- Tempus AI and Northwestern Medicine partnered to enhance AI-powered clinical care and boost investor confidence.
- Tempus AI and AstraZeneca announced a foundational model partnership.
- FDA granted 510(k) clearance for Tempus AI's ECG-Low EF software.
- Tempus AI's selling activity was reversed following the dismissal of a critical report by TD Cowen.
- Paige, acquired by Tempus AI, has received FDA clearance, while AI stocks continue to benefit from onshoring and tariff trends.
- Analyst firm TD Cowen noted that due to genomic volume growth, Tempus AI benefits from Trump-era tariffs and onshoring trends.
- Pelosi's trades fueled speculative sentiment around Tempus AI as of June 25, 2025.
- Recursion Pharmaceuticals, Merck KGaA, and Tempus expanded collaborations to leverage multimodal datasets and launch AI models for drug discovery.
- Eric Lefkofsky joined Tempus as Founder and CEO, and Jim Rogers joined as CFO, both on July 22, 2025.
- Eric Lefkofsky was named the Founder and CEO of Tempus on August 8, 2025.
- Tempus stock underperformed the S&P 500 composite on August 8, 2025.